Paul B. Manning - 26 Jul 2021 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Paul B. Manning
Issuer symbol
CADL
Transactions as of
26 Jul 2021
Net transactions value
$0
Form type
3
Filing time
26 Jul 2021, 21:24:06 UTC
Previous filing
08 Jul 2021
Next filing
29 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Series B Preferred Stock 26 Jul 2021 Common Stock 679,158 By Paul B. Manning Revocable Trust F1, F2
holding CADL Series B Preferred Stock 26 Jul 2021 Common Stock 553,752 By BKB Growth Investments, LLC F1, F3
holding CADL Warrants to purchase Common Stock 26 Jul 2021 Common Stock 679,158 $6.81 By Paul B. Manning Revocable Trust F2
holding CADL Warrants to purchase Common Stock 26 Jul 2021 Common Stock 553,752 $6.81 By BKB Growth Investments, LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series B Preferred Stock has no expiration date.
F2 The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.